Biocon Ltd

Biocon Ltd

Biocon Ltd has announced the commercial launch of Yesafili, a biosimilar to Eylea 2 mg, in the United States. The product is a vascular endothelial growth factor (VEGF) inhibitor used to treat various types of ophthalmology conditions.

Biocon Ltd

Biocon Ltd has commercially launched Yesafili, a biosimilar Aflibercept, in the United States, expanding its global presence in ophthalmology and increasing access to life-changing medicines for patients with eye conditions.

Biocon Ltd

Biocon Ltd receives Health Canada approval for Yesintek (ustekinumab) Autoinjector Pen, expanding its portfolio of immunology products in Canada.

Biocon Ltd

Biocon Ltd has announced an earnings conference call for analysts and investors to discuss Q1 FY 2026-27 financial results, scheduled for August 6, 2026.

Biocon Ltd

Biocon Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2026 to consider and approve Intimation for the Board Meeting and Earnings Conference Call for Analysts and Investors.

Biocon Ltd

Biocon Ltd informs that Mr. Bobby Kanubhai Parikh has completed his second term as an Independent Director and ceased to be a Director of the Company w.e.f. July 22, 2026. The Board appreciates his contributions and gratitude.

Biocon Ltd

Biocon Limited announced that its partner, Duopharma Biotech Berhad, secured multiple insulin contracts valued over MYR 225 million from the Ministry of Health, Malaysia. Biocon's Malaysian subsidiary, Biocon Sdn. Bhd., will supply various insulin products including recombinant human insulin, insulin glargine, and insulin aspart under these contracts, which include a three-year agreement for human insulin (~MYR 155.27 million) and two 2-year agreements for insulin glargine (~MYR 18 million) and insulin aspart (~MYR 52.5 million). This reinforces Biocon's long-standing commitment and presence in Malaysia's diabetes care market.

Biocon Ltd

Biocon Ltd has issued a communication to its shareholders regarding the deduction of Tax at Source (TDS) on the final dividend recommended for the Financial Year 2025-26. The Board had recommended a final dividend of Re. 0.50 per equity share, which is subject to shareholder approval at the upcoming Annual General Meeting on August 06, 2026, with a record date of July 03, 2026. The company details the varying TDS rates based on shareholder categories and residential status and advises shareholders to update their details for accurate tax processing.